Related Experiment Videos
The cost of treating hypertension: can we keep it under control without compromising the level of care?
1Yale University School of Medicine, New Haven, Connecticut, USA.
Insights
Hypertension treatment costs can be managed effectively without impacting patient outcomes. Avoiding unnecessary expensive tests and optimizing medication strategies are key to cost-effective hypertension care.
Area of Science:
- Cardiology
- Health Economics
Background:
- Hypertension treatment incurs significant healthcare costs.
- Current diagnostic and treatment strategies may not be cost-effective.
Purpose of the Study:
- To analyze cost-containment strategies in hypertension management.
- To evaluate the impact of diagnostic and treatment choices on healthcare expenditure and patient outcomes.
Main Methods:
- Review of national recommendations for hypertension evaluation.
- Analysis of costs associated with diagnostic procedures (echocardiograms, ambulatory monitoring).
- Assessment of treatment-related costs including medication choices and adherence to treatment goals.
Main Results:
- Expensive diagnostic tests like echocardiograms and ambulatory monitoring are not routinely recommended and add substantial costs without proven outcome improvement.
- Unnecessary costs arise from premature labeling, prolonged lifestyle modification, frequent medication switching, and failure to achieve blood pressure goals.
- Less expensive therapies are often sufficient for initial management, with cost-effectiveness guiding choices only when benefits are proven equal.
- Benefits of antihypertensive therapy, including prevention of left ventricular hypertrophy, are underestimated, while cost per quality-adjusted life-year may be overestimated.
Conclusions:
- Hypertension treatment costs can be contained by adhering to evidence-based diagnostic and therapeutic guidelines.
- Optimizing medication selection and ensuring treatment to goal blood pressure are crucial for cost-effective care.
- Pharmacoeconomic models should be interpreted cautiously to avoid misleading clinical decisions.
Abstract:
The cost of hypertension treatment can be contained without compromising outcome. National recommendations for the routine diagnostic evaluation of hypertensive subjects do not include echocardiograms or ambulatory monitoring. These are expensive procedures, which, if performed in only a fraction of the total hypertensive population, would add several billion dollars to the cost of care. At present there are no data indicating that outcome of treatment would be improved. Costs of labeling before a definitive diagnosis is made, continuing lifestyle modification too long, medication switching, and not treating to goal blood pressures also increase cost without increased benefit. Although there are special indications for the more expensive newer medications, the majority of patients can be managed, at least initially, with less expensive therapies. Cost should not be a consideration, however, if one therapy has been shown to be more beneficial than another. Finally, the benefits of antihypertensive drug therapy have been underestimated because of the lack of consideration of prevention of left ventricular hypertrophy or progression to more severe disease by early treatment. On the other hand, the cost per quality of life-years saved has been overestimated. Pharmacoeconomic models may serve to mislead practitioners regarding treatment decisions.